SRP-5051

DRUG2 trials

Sponsors

Sarepta Therapeutics, Inc.

Conditions

Muscular Dystrophy, Duchenne

Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)

CompletedNCT03375255

Sarepta Therapeutics, Inc.Muscular Dystrophy, Duchenne

Start: 2018-02-05End: 2019-08-19Updated: 2022-07-06

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

TerminatedNCT03675126

Sarepta Therapeutics, Inc.Muscular Dystrophy, Duchenne

Start: 2018-12-19End: 2021-08-25Updated: 2024-09-19